Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects
Experimental and Clinical Endocrinology & Diabetes · 2024-12 · 132 (12) · 723-731
DOI: 10.1055/a-2317-0801 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, online erschienen am 14.06.2024. Verfasst von Mario Detomas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Cushing Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Clinician Scientist program RISE funded by the Else-Kröner-Fresenius-Stiftung & the Eva-Luise–und-Horst-Köhler Stiftung.
Abstract (Originalsprache)
Endogenous Cushing’s syndrome (CS) is a rare disease characterized by a glucocorticoid excess. If inadequately treated, hypercortisolism can lead to increased morbidity and mortality. Surgical removal of the underlying tumor is the first-line treatment but is sometimes not feasible or even contraindicated. Additionally, in cases with severe CS, rapid control of hypercortisolism may be required. In these scenarios, steroidogenesis inhibitors represent a therapeutic alternative to surgery. Over the last years, the knowledge of the broad therapeutic effects of steroidogenesis inhibitors per se and the number of available drugs have increased. However, large comparative studies are still lacking. Accordingly, the decision on which drug to be used in a certain patient or clinical setting may be difficult. This review aims to summarize the main characteristics of steroidogenesis inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
- Medicover Oldenburg MVZ, Oldenburg, Germany.
Förderung
- Clinician Scientist program RISE funded by the Else-Kröner-Fresenius-Stiftung & the Eva-Luise–und-Horst-Köhler Stiftung
Zitieren
APA
Detomas, M., Deutschbein, T., & Altieri, B. (2024). Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects. Experimental and Clinical Endocrinology & Diabetes, 132(12), 723-731. https://doi.org/10.1055/a-2317-0801
Vancouver
Detomas M, Deutschbein T, Altieri B. Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects. Experimental and Clinical Endocrinology & Diabetes. 2024;132(12):723-731. doi:10.1055/a-2317-0801
BibTeX
@article{Detomas2024,
author = {Detomas, Mario and Deutschbein, Timo and Altieri, Barbara},
title = {Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2024},
volume = {132},
number = {12},
pages = {723--731},
doi = {10.1055/a-2317-0801}
}
EUVIMED